Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 678.55K | 1.50M | 583.23K | 0.00 | 0.00 | 0.00 |
Gross Profit | 819.30K | 1.48M | 576.18K | -186.44K | -271.68K | -229.61K |
EBITDA | -14.79M | -12.94M | -14.28M | -112.48M | -36.86M | -53.25M |
Net Income | -13.85M | -12.96M | -14.29M | -224.88M | -36.54M | -53.92M |
Balance Sheet | ||||||
Total Assets | 17.31M | 23.98M | 22.65M | 30.16M | 56.82M | 92.81M |
Cash, Cash Equivalents and Short-Term Investments | 16.53M | 22.85M | 21.61M | 28.79M | 53.08M | 89.02M |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 190.47K | 335.16K |
Total Liabilities | 3.90M | 4.67M | 4.39M | 4.51M | 7.32M | 15.41M |
Stockholders Equity | 14.14M | 19.31M | 18.26M | 25.64M | 49.51M | 77.40M |
Cash Flow | ||||||
Free Cash Flow | -12.74M | -13.57M | -12.27M | -25.01M | -37.69M | -41.83M |
Operating Cash Flow | -12.74M | -13.56M | -12.18M | -25.01M | -37.69M | -41.80M |
Investing Cash Flow | -209.00 | -15.48K | -93.09K | 0.00 | 0.00 | -25.71K |
Financing Cash Flow | 573.98K | 14.82M | 5.14M | 682.97K | 1.75M | 150.95K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $9.17M | 4.67 | -43.39% | ― | -100.00% | 49.47% | |
53 Neutral | $19.20M | ― | -321.37% | ― | 4455.07% | 77.31% | |
51 Neutral | $7.77B | -0.12 | -39.78% | 2.21% | 22.68% | -1.42% | |
49 Neutral | $9.19M | ― | -494.11% | ― | ― | -219.97% | |
42 Neutral | $9.95M | ― | -362.79% | ― | -48.01% | 33.60% | |
40 Underperform | $9.26M | ― | -67.54% | ― | -34.07% | 23.79% | |
39 Underperform | $8.00M | ― | -285.93% | ― | ― | 53.79% |
Aprea Therapeutics has announced promising preliminary safety results for its WEE1 inhibitor, APR-1051, showcased at an international oncology conference. The Phase 1 trial indicates APR-1051 is safe and well-tolerated without serious side effects, presenting potential as a treatment for advanced solid tumors. With ongoing trials in the U.S., the company is optimistic about further exploring APR-1051’s therapeutic potential, aiming for more efficacy data in 2025.